EDINBURGH, Scotland, Oct. 3, 2024 /PRNewswire/ — TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a sponsored research agreement with Carnegie Mellon University to explore the potential use of artificial intelligence to optimize the patient screening process.
The Company will partner with Dr. Wei Wu, […]
TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for …